Response to Initial Therapy of Differentiated Thyroid Cancer Predicts the Long-Term Outcome Better than Classical Risk Stratification Systems
Table 1
Clinical outcomes at the end of follow-up period.
(1) No evidence of disease after initial therapy (i) Undetectable suppressed and stimulated TG (ii) No evidence of structural disease by neck US and diagnostic 131I whole body scan (iii) No need for additional therapy
(2) No evidence of disease after additional therapy (i) Undetectable suppressed and stimulated TG (ii) No evidence of structural disease by neck US, diagnostic 131I whole body scan, and other cross-sectional imaging if performed (CT scan, MRI, FDG-PET scan, bone scintigraphy) (iii) Need for additional therapy (surgery, second dose of ablative 131I, and chemotherapy)
(3) Persistent biochemical disease (i) Suppressed TG ≥ 1 ng/mL or stimulated TG ≥ 2 ng/mL (ii) No evidence of structural disease by neck US, diagnostic 131I whole body scan, and other cross-sectional imaging if performed (CT scan, MRI, FDG-PET scan, bone scintigraphy)
(4) Persistent structural disease Any evidence of disease on neck US, diagnostic 131I whole body scan, and other cross-sectional imaging (CT scan, MRI, FDG-PET scan, bone scintigraphy) or biopsy proven disease
